Cargando…

Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China

OBJECTIVE: Limited economic evaluation data for rivaroxaban compared with standard of care (SoC) exists in China. The objective of this analysis was to evaluate the cost-effectiveness of rivaroxaban compared with current SoC (enoxaparin overlapped with warfarin) for the treatment of acute deep vein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Li, Wu, Jingjing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394175/ https://www.ncbi.nlm.nih.gov/pubmed/32737096 http://dx.doi.org/10.1136/bmjopen-2020-038433

Ejemplares similares

A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia
por: Derseh, Manaye Tamrie, et al.
Publicado: (2021)

A Pilot Study of Home Treatment of Deep Vein Thrombosis With Subcutaneous Once-Daily Enoxaparin Plus Warfarin
por: Bishop, Beverly, et al.
Publicado: (2006)

Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty
por: Çiçek, Necati, et al.
Publicado: (2021)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J’xactly) study
por: Okumura, Yasuo, et al.
Publicado: (2018)

Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study
por: Evans, Alison, et al.
Publicado: (2020)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)

Renal outcomes of rivaroxaban compared with warfarin in Asian patients with nonvalvular atrial fibrillation: A nationwide population-based cohort study
por: Lee, So-Ryoung, et al.
Publicado: (2023)

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions
por: Margolis, Jay M., et al.
Publicado: (2016)

Warfarin-induced deep vein thrombosis
por: Binymin, Khalid A, et al.
Publicado: (2014)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
por: Lin, Dong, et al.
Publicado: (2021)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Reversal of Bioprosthetic Aortic Valve Thrombosis Using Rivaroxaban—A Case Report
por: Sharma, Harish, et al.
Publicado: (2020)

Use of oral rivaroxaban in cerebral venous thrombosis
por: Maqsood, Muhammad, et al.
Publicado: (2020)

Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report
por: Schiavoni, Mario, et al.
Publicado: (2016)

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization
por: Yu, Qingyuan, et al.
Publicado: (2022)

High fibrinogen and mixed proximal and distal thrombosis are associated with the risk of residual venous thrombosis in patients with posttraumatic deep vein thrombosis
por: Liu, Yating, et al.
Publicado: (2023)

Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban
por: Piati, Polyana Klomfass, et al.
Publicado: (2019)

The Role of Warfarin and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis
por: Fayyaz, Muniba, et al.
Publicado: (2019)

Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
por: Thaler, Johannes, et al.
Publicado: (2015)

Extensive Deep Vein Thrombosis after Electrophysiology Study
por: Kwon, Chang Hee
Publicado: (2020)

Warfarin-Induced Skin Necrosis Despite Enoxaparin Bridging Therapy
por: Wali, Mohamed, et al.
Publicado: (2022)

The association between iliac vein compression degree and characteristics of first diagnosed left lower extremity deep vein thrombosis
por: Shi, Yadong, et al.
Publicado: (2022)

Hyperglycemia may increase deep vein thrombosis in trauma patients with lower limb fracture
por: Liu, Xiaojie, et al.
Publicado: (2022)

Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study
por: Khorvash, Fariborz, et al.
Publicado: (2021)

Upper Extremity Deep Vein Thrombosis and Asymptomatic Vein Occlusion in Patients With Transvenous Leads: A Systematic Review and Meta-Analysis
por: Duijzer, Daniël, et al.
Publicado: (2021)

Platelet accumulation in an endothelium-coated elastic vein valve model of deep vein thrombosis is mediated by GPIbα—VWF interaction
por: Baksamawi, Hosam Alden, et al.
Publicado: (2023)

Risk factors and a predictive model for nonfilter-associated inferior vena cava thrombosis in patients with lower extremity deep vein thrombosis
por: Gong, Maofeng, et al.
Publicado: (2023)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Efficacy and safety of enoxaparin as deep vein thrombosis prophylaxis in critically ill patients
por: Al-Hubail, R, et al.
Publicado: (2012)

Searching for a Common Thrombo-Inflammatory Basis in Patients With Deep Vein Thrombosis or Peripheral Artery Disease
por: Kremers, Bram M. M., et al.
Publicado: (2019)

A Case of Renal Vein Thrombosis Associated With COVID-19 Treated With Rivaroxaban
por: Asleson, Louise, et al.
Publicado: (2022)

Hemorrhagic Cholecystitis after Warfarin Use for Deep Vein Thrombosis
por: Donn, Eric, et al.
Publicado: (2018)

Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care
por: González-Pérez, Antonio, et al.
Publicado: (2022)

Enoxaparin sodium: Lack of efficacy in deep vein thrombosis prophylaxis: 3 case reports
Publicado: (2020)

Incidence and risk factors of deep vein thrombosis in patients with spinal cord injury: a systematic review with meta-analysis
por: Shang, Zhizhong, et al.
Publicado: (2023)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: A randomized clinical trial
por: Yao, Wei, et al.
Publicado: (2021)

New warfarin anticoagulation management model after heart valve surgery: rationale and design of a prospective, multicentre, randomised trial to compare an internet-based warfarin anticoagulation management model with the traditional warfarin management model
por: Zhu, Zhihui, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fbt8csj7kc4g07evil0ph96v7e